Veru (VERU) AI Stock Analysis

• Market Cap: $37.56M
• Dividend Yield: N/A
• Average Volume (3M): 160.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: -100.00%
• EPS Growth: 55.10%
• Country: US
• Employees: 210
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 16,050,320
• 10 Day Avg. Volume: 244,731
• 30 Day Avg. Volume: 160,942
• PEG Ratio: 0.05
• Price to Book (P/B): 3.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 1.96
• Enterprise Value/Revenue: 11.05
• Enterprise Value/Gross Profit: 28.69
• Enterprise Value/Ebitda: -2.06
• 1Y Price Target: $25.00
• Price Target Upside: 968.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.37
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(6.84% Upside)

Veru's overall stock score is primarily impacted by its weak financial performance and valuation concerns, with ongoing losses and cash flow challenges. While technical indicators are bearish, the positive clinical trial results and regulatory progress provide some optimism for future growth, albeit overshadowed by financial instability.

Positive Factors

Regulatory Progress

Securing FDA feedback and clarity on the Phase 3 program enhances the potential for successful drug approval, supporting long-term growth.

Clinical Trial Success

Successful clinical trials bolster Veru's drug pipeline credibility, potentially leading to new market opportunities and revenue streams.

New Product Development

Developing new formulations with extended patent protection secures competitive advantage and supports long-term revenue potential.

Negative Factors

Financial Loss

Ongoing financial losses indicate operational inefficiencies and challenge the company's ability to fund growth and innovation.

Cash Flow Concerns

Insufficient cash flow raises concerns about Veru's ability to sustain operations and invest in future growth without additional financing.

Revenue Decline

Declining revenues reflect potential market challenges and may hinder Veru's ability to achieve profitability and long-term growth.

Veru Business Overview & Revenue Model

Company Description

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

How the Company Makes Money

Veru generates revenue primarily through the commercialization of its pharmaceutical products, which includes sales from its approved therapies. The company also engages in research and development partnerships with other pharmaceutical companies, which can provide additional funding and resources in exchange for shared rights to new drugs. Additionally, Veru may receive milestone payments and royalties from licensing agreements related to its drug candidates. The ongoing development of its pipeline products and successful clinical trials are critical to expanding its revenue streams.

Veru Financial Statement Overview

Summary

Veru's financial performance is challenged by declining revenues and significant net losses, resulting in a negative net profit margin. Despite a strong equity base and low leverage, the company struggles with profitability and cash flow generation, indicating operational inefficiencies.

Income Statement

Veru's income statement reveals significant challenges with profitability. The company has experienced declining revenues, with a 12.7% decrease from the previous year, and a negative net profit margin of -260.8% TTM due to substantial net losses. Although gross profit margin remains positive at 31.9%, the EBIT and EBITDA margins are severely negative, indicating operational inefficiencies. This suggests that Veru is struggling to manage its operating expenses effectively in relation to its revenue.

Balance Sheet

Veru maintains a relatively moderate debt-to-equity ratio of 0.13 TTM, indicating a conservative approach to leveraging. The equity ratio is 66.9%, which showcases a strong reliance on equity financing and a robust capital base. However, the return on equity is negative at -144.4% TTM, reflecting the company's inability to generate profits from its equity base. This highlights a need for improvement in generating returns for shareholders.

Cash Flow

The cash flow statement shows that Veru is facing challenges with cash generation, having negative operating cash flow and free cash flow in the TTM period. The free cash flow to net income ratio is negative, indicating that the company is not converting its net income into free cash flow. This raises concerns about Veru's ability to sustain its operations and invest in future growth without additional financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.66M	0.00	16.89M	16.30M	39.35M	61.26M
Gross Profit	2.56M	0.00	5.85M	7.57M	30.59M	47.93M
EBITDA	-35.79M	9.07M	-36.20M	-89.98M	-79.23M	9.75M
Net Income	-32.71M	-22.73M	-37.80M	-93.15M	-83.78M	7.39M
Balance Sheet
Total Assets	27.33M	29.84M	60.42M	50.02M	135.36M	178.15M
Cash, Cash Equivalents and Short-Term Investments	15.01M	15.79M	24.92M	9.63M	80.19M	122.36M
Total Debt	3.25M	3.12M	13.86M	14.41M	15.88M	13.74M
Total Liabilities	11.99M	11.50M	28.10M	30.34M	52.56M	25.85M
Stockholders Equity	15.34M	18.33M	32.32M	19.68M	82.80M	152.29M
Cash Flow
Free Cash Flow	-28.98M	-30.04M	-21.84M	-88.68M	-48.24M	-15.95M
Operating Cash Flow	-28.92M	-30.04M	-21.68M	-88.01M	-47.51M	-15.57M
Investing Cash Flow	19.00M	25.14M	146.21K	6.33M	4.27M	14.62M
Financing Cash Flow	-4.22M	-4.22M	36.83M	11.11M	1.07M	109.72M

Veru Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERU, the sentiment is Negative. The current price of 2.34 is below the 20-day moving average (MA) of 2.42, below the 50-day MA of 2.82, and below the 200-day MA of 4.39, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 41.27 is Neutral, neither overbought nor oversold. The STOCH value of 31.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERU.

Veru Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INMB	52 Neutral	$47.06M	-0.83	-155.77%	―	19.05%	2.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KPTI	49 Neutral	$127.37M	-0.51	―	―	-3.98%	-29.94%
VERU	45 Neutral	$37.56M	-1.84	-61.92%	―	-100.00%	55.10%
CUE	42 Neutral	$21.99M	-0.53	-195.19%	―	-25.51%	49.72%
CELU	38 Underperform	$37.59M	-0.40	―	―	-15.81%	-113.06%

Veru Corporate Events

Veru Announces Public Offering to Raise $23.4 Million

On October 30, 2025, Veru Inc. entered into an underwriting agreement with Canaccord Genuity LLC for a public offering of 8,400,000 shares of its common stock, along with Series A and B warrants, expected to raise approximately $23.4 million. The proceeds will primarily fund the development of enobosarm, focusing on the Phase 2b PLATEAU clinical study, and for general corporate purposes. The offering is expected to close on or about October 31, 2025, subject to customary conditions, and aims to strategically position Veru in the biopharmaceutical market by advancing its clinical pipeline.

The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.

Veru Inc. Completes Promising Phase 2 Study on Enobosarm for Weight Management

Veru Inc. recently completed a Phase 2 clinical study titled ‘A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management.’ The primary objective was to assess the impact of enobosarm on total lean mass in patients using GLP-1 receptor agonists for weight management. This study is significant as it explores potential enhancements in body composition, which could benefit patients struggling with muscle loss and obesity.

Veru Settles Debt with Onconetix Agreement

Veru Inc. entered into a Settlement Agreement with Onconetix, Inc., formerly known as Blue Water Vaccines Inc., to resolve outstanding payment obligations under previously issued promissory notes. On September 22, 2025, Veru agreed to accept a combination of cash, preferred stock, and warrants in full satisfaction of the debt, leading to the termination of the promissory notes and related agreements upon payment on September 24, 2025.

The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.

Veru Inc’s Earnings Call: Clinical Success Amid Financial Struggles

Veru Inc’s recent earnings call presented a mixed sentiment, with positive clinical trial results and a promising regulatory pathway for its drug Inovasarm, counterbalanced by financial challenges and cash flow concerns. Despite these financial hurdles, the company’s advancements in drug development indicate a hopeful outlook.

Veru Regains Nasdaq Compliance with Bid Price

On August 26, 2025, Veru Inc. announced that it has regained compliance with Nasdaq’s minimum bid price requirement, a crucial step for maintaining its listing on the exchange. This follows a previous notification from August 29, 2024, where the company was given a deadline to meet the requirement after its stock price fell below $1.00 for 30 consecutive days.

The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.

Veru Inc. Reports Positive Results and Progress

Veru Inc. is a late clinical stage biopharmaceutical company that develops innovative medicines for treating cardiometabolic and inflammatory diseases, with a focus on drugs like enobosarm and sabizabulin.

Veru Implements 1-for-10 Reverse Stock Split

On August 8, 2025, Veru Inc. implemented a 1-for-10 reverse stock split of its common stock, which was approved by shareholders on July 25, 2025. The reverse stock split aims to help Veru regain compliance with Nasdaq’s $1.00 minimum bid price requirement, and it will affect all shareholders uniformly without changing ownership percentages, except for cash payments in lieu of fractional shares.

The most recent analyst rating on (VERU) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.